Barclays PLC reissued their buy rating on shares of Puma Biotechnology Inc (NYSE:PBYI) in a research note issued to investors on Friday morning. The brokerage currently has a $122.00 target price on the biopharmaceutical company’s stock, up from their previous target price of $103.00.
Other equities analysts have also issued research reports about the company. J P Morgan Chase & Co reissued a buy rating on shares of Puma Biotechnology in a research note on Tuesday, August 1st. BidaskClub lowered Puma Biotechnology from a strong-buy rating to a buy rating in a research report on Thursday, August 10th. Citigroup Inc. reaffirmed a buy rating and set a $114.00 price target on shares of Puma Biotechnology in a research report on Tuesday, July 18th. Stifel Nicolaus reaffirmed a buy rating and set a $118.00 price target (up previously from $105.00) on shares of Puma Biotechnology in a research report on Tuesday, July 18th. Finally, Bank of America Corporation reaffirmed a buy rating and set a $117.00 price target (up previously from $100.00) on shares of Puma Biotechnology in a research report on Friday, July 21st. One research analyst has rated the stock with a sell rating, one has issued a hold rating, eight have given a buy rating and one has given a strong buy rating to the company. The company has a consensus rating of Buy and a consensus target price of $130.67.
Puma Biotechnology (NYSE PBYI) traded down $24.20 during trading hours on Friday, reaching $103.00. The company’s stock had a trading volume of 5,677,100 shares, compared to its average volume of 1,118,516. Puma Biotechnology has a 1 year low of $28.35 and a 1 year high of $136.90.
Puma Biotechnology (NYSE:PBYI) last released its earnings results on Thursday, November 9th. The biopharmaceutical company reported ($2.07) earnings per share for the quarter, beating the consensus estimate of ($2.50) by $0.43. The company had revenue of $6.10 million during the quarter, compared to analyst estimates of $3.78 million. During the same period in the previous year, the company posted ($1.11) EPS.
In related news, SVP Richard Paul Bryce sold 15,000 shares of Puma Biotechnology stock in a transaction that occurred on Thursday, September 7th. The stock was sold at an average price of $100.09, for a total value of $1,501,350.00. Following the sale, the senior vice president now owns 28,239 shares of the company’s stock, valued at approximately $2,826,441.51. The sale was disclosed in a legal filing with the SEC, which can be accessed through this link. 22.70% of the stock is currently owned by company insiders.
A number of institutional investors have recently made changes to their positions in PBYI. Parametric Portfolio Associates LLC acquired a new stake in Puma Biotechnology in the 1st quarter valued at approximately $257,000. Teachers Advisors LLC raised its position in Puma Biotechnology by 2.0% in the 1st quarter. Teachers Advisors LLC now owns 145,197 shares of the biopharmaceutical company’s stock valued at $5,401,000 after buying an additional 2,824 shares during the last quarter. Legal & General Group Plc raised its position in Puma Biotechnology by 2.8% in the 1st quarter. Legal & General Group Plc now owns 9,297 shares of the biopharmaceutical company’s stock valued at $346,000 after buying an additional 249 shares during the last quarter. Vanguard Group Inc. raised its position in Puma Biotechnology by 4.4% in the 1st quarter. Vanguard Group Inc. now owns 2,428,909 shares of the biopharmaceutical company’s stock valued at $90,355,000 after buying an additional 101,722 shares during the last quarter. Finally, Geode Capital Management LLC raised its position in Puma Biotechnology by 17.3% in the 1st quarter. Geode Capital Management LLC now owns 232,371 shares of the biopharmaceutical company’s stock valued at $8,644,000 after buying an additional 34,190 shares during the last quarter. 80.98% of the stock is currently owned by institutional investors and hedge funds.
Puma Biotechnology Company Profile
Puma Biotechnology, Inc is a biopharmaceutical company that focuses on the development and commercialization of products for the treatment of cancer. The Company focuses on in-licensing the development and commercialization rights to over three drug candidates, including PB272 (neratinib (oral)), PB272 (neratinib (intravenous)) and PB357.
Receive News & Ratings for Puma Biotechnology Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Puma Biotechnology Inc and related companies with MarketBeat.com's FREE daily email newsletter.